By testing multiple treatment strategies (such as add-on or alternative therapy) against the existing standard of care (SoC), we were able to confirm that AXL inhibitors induce changes in the tumor microenvironment (TME), in addition to tumor suppression. Here, AXL is linked to neoplasm.